Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global POC Diagnostics Market Driven by Growing Demand for Portable and Handheld Near-Patient Devices

By LabMedica International staff writers
Posted on 20 Dec 2022

Point of care (POC) diagnostics is medical diagnostic testing that is performed at or near the POC, and at the place and time of patient care. POC diagnostics includes blood glucose testing, rapid coagulation testing, drugs of abuse screening, blood gas and electrolyte analysis, quick cardiac marker diagnostic, pregnancy testing, infectious disease testing, cholesterol screening, hemoglobin diagnostic, etc. POC diagnostic testing differs from traditional diagnostics that is restricted to the laboratory. POC diagnostic tests can be performed at the bedside and brings the test immediately to the patient. POC diagnostic testing raises the likelihood of the patient receiving the test results quickly and improves clinical management. Portable and handheld instruments are used in POC diagnostics, enabling the test results to be shared quickly with the patients. It helps in the rapid detection of analytes near the patient, facilitates better disease diagnosis, monitoring, and management, and enables quick medical decisions. POC diagnostics plays a vital role in patient management by reducing the time to treatment.

The COVID-19 outbreak led to increased demand for POC diagnosis. This has been accompanied by the increasing incidence of chronic and infectious diseases globally. As a result, there has been growing demand for portable, transportable, and handheld devices that is fueling the growth of the POC diagnostics market. In addition, the increase in technological advancements has also contributed significantly to the market growth. The global POC diagnostics market is projected to grow at a CAGR of 11.1% from USD 39.91 billion in 2022 to USD 93.21 billion by 2030, driven by the rising incidence of chronic diseases such as cardiovascular disorders, diabetes, and infectious diseases, as well as an increasing geriatric population. These are the latest findings of Precedence Research (Ottawa, Canada), a market research firm.

Rapid technological advancements such as the emergence of cloud-based deep learning systems and chip technology miniaturization are expected to expand the applications of POC diagnostics. For instance, lab-on-a-chip technology is now used at the POC. The development of nanoparticle-based POC technology has also attracted the attention of the market players and helped doctors to take advantage of nanoparticles for the diagnosis of various chronic conditions. The market players are adopting modern technologies such as artificial intelligence (AI) to produce more efficient products and are focusing on integrating ELISA into products for diagnosing infectious diseases. However, the high cost of product development due to various technology areas depending upon the test type could hamper market growth.

Based on product, the blood glucose monitoring segment dominates the POC diagnostics market with the highest revenue share due to increasing demand for products for monitoring blood sugar levels and growing preference for home glucose testing. On the other hand, the infectious diseases segment is expected to register a promising CAGR during the forecast period due to the rising prevalence of various contagious diseases. Based on end user, the hospital bedside segment dominates the POC diagnostics market with the highest revenue share due to the rising prevalence of chronic diseases which require long-term care and frequent monitoring. The increasing awareness about the availability of cost-effective and highly innovative POC diagnostics creates a positive outlook for the market. On the other hand, the urgent care & retail clinics segment are expected to register a promising CAGR over the coming years due to the growing number of clinics and urgent care centers.

Based on region, North America dominated the global POC diagnostics market with the largest revenue share due to the high prevalence of lifestyle diseases, increasing awareness of self-testing and home care kits, and rapid technological advancements in the region. On the other hand, the Asia-Pacific market for POC diagnostics is expected to register a promising CAGR during the forecast period due to the increasing number of market players and growing use of POC diagnostics in the developing countries.

Related Links:
Precedence Research 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Multi-Function Pipetting Platform
apricot PP5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.